Combination therapies with JAK inhibitors
| JAK inhibitor . | Added drug . | Mechanism of action of added drug . | Patient population . | Trial no. . |
|---|---|---|---|---|
| Ruxolitinib | Navitoclax | BCL2/BCLXL/BCLw inhibitor | MF | NCT03222609 |
| Ruxolitinib | Umbralisib | PI3Kδ inhibitor | PV, MF | NCT02493530 |
| Ruxolitinib | Decitabine | Hypomethylating agent | AP and BP MPNs | NCT02076191 |
| Ruxolitinib | Enasidenib | IDH2 inhibitor | AP and BP MPNs with an IDH2 mutation | NCT04281498 |
| Ruxolitinib | CPI-0610 | BET inhibitor | MF | NCT02158858 |
| Ruxolitinib | KRT-232 | MDM2 inhibitor | TP53 wild-type MF with previous ruxolitinib exposure | NCT04485260 |
| Fedratinib | Luspatercept | ActRII ligand trap | MF with previous ruxolitinib exposure | NCT03755518 |
| JAK inhibitor . | Added drug . | Mechanism of action of added drug . | Patient population . | Trial no. . |
|---|---|---|---|---|
| Ruxolitinib | Navitoclax | BCL2/BCLXL/BCLw inhibitor | MF | NCT03222609 |
| Ruxolitinib | Umbralisib | PI3Kδ inhibitor | PV, MF | NCT02493530 |
| Ruxolitinib | Decitabine | Hypomethylating agent | AP and BP MPNs | NCT02076191 |
| Ruxolitinib | Enasidenib | IDH2 inhibitor | AP and BP MPNs with an IDH2 mutation | NCT04281498 |
| Ruxolitinib | CPI-0610 | BET inhibitor | MF | NCT02158858 |
| Ruxolitinib | KRT-232 | MDM2 inhibitor | TP53 wild-type MF with previous ruxolitinib exposure | NCT04485260 |
| Fedratinib | Luspatercept | ActRII ligand trap | MF with previous ruxolitinib exposure | NCT03755518 |